Ginkgo Bioworks (NYSE: DNA) shares were fairly flat Tuesday. The Boston-based Gingko, which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O'Sullivan as Head of Commercial for Ginkgo Automation. Brian joins Ginkgo Automation from HighRes Biosolutions, where he led their commercial efforts.
In his new role, Brian will oversee all revenue generating functions, including sales, business development, channel partnerships, marketing, and customer success, at a pivotal moment for Ginkgo Automation.
Over the past year, the business unit has quickly evolved from supporting Ginkgo's internal R&D to providing its modular RAC (Reconfigurable Automation Cart) hardware, Catalyst scheduling and orchestration software, and remote monitoring and error resolution services to external clients.
Ginkgo Automation, says this morning’s news release, “now serves a rapidly expanding customer base across biopharma, diagnostics, and national laboratories.”
"Brian has consistently built top-performing commercial teams that translate advanced technology into clear customer value," said Will Serber, GM, Ginkgo Automation. "His expertise in developing and executing capex and software solutions, executing large automation transactions, and his robust network across the life sciences market uniquely positions us to scale globally and maximize the power of our platform."
DNA shares began trading Tuesday morning with a slight gain of seven cents to $11.95.
